T-MAXIMUM B7-H3-TARGETED ALLOGENEIC CAR-T THERAPY MT027 RECEIVES FDA FAST TRACK DESIGNATION, ACCELERATING GLOBAL DEVELOPMENT FOR INTRACRANIAL SOLID TUMORS

Reuters · 2d ago

Please log in to view news